Weight regain is common after stopping either Wegovy (semaglutide) or Zepbound (tirzepatide) in the withdrawal studies available. In the STEP 1 semaglutide extension, participants regained about two-thirds of the weight they had lost during the year after treatment and lifestyle intervention ended. In SURMOUNT-4, people switched from tirzepatide to placebo gained weight on average over the next 52 weeks, while people who continued tirzepatide lost more. Those are group averages from different trials, not a prediction for one person. Do not stop, taper, or restart without discussing an individual plan with the prescribing clinician.
The short answer
Stopping a GLP-1/GIP weight-management medicine does not guarantee that all lost weight will return, but regain was the average outcome in both major withdrawal studies cited here. The amount varied by study design, treatment duration, starting weight, and participant characteristics.
As an Amazon Associate I earn from qualifying purchases.
In the semaglutide STEP 1 extension, participants had lost an average of 17.3% of their initial body weight after 68 weeks of treatment. During the following 52 weeks without semaglutide and the trial’s lifestyle intervention, they regained 11.6 percentage points of body weight, leaving a mean net loss of 5.6% from their original baseline at week 120. The study authors described this as regaining about two-thirds of the prior loss.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallIn SURMOUNT-4, participants first received tirzepatide for 36 weeks and lost an average of 20.9%. Those switched to placebo then had a 14.0% mean increase in body weight from week 36 over the next 52 weeks. Participants who stayed on tirzepatide lost an additional 5.5% on average.
#1 Best Overall
These trials were not head-to-head comparisons. They used different protocols and populations, so their percentages should not be treated as a direct ranking of Wegovy versus Zepbound or as an individualized forecast.
What the Wegovy withdrawal study found
STEP 1 extension design
The STEP 1 extension followed 327 people from the original STEP 1 trial. Participants had obesity, or overweight with a weight-related health condition, and did not have diabetes. They had received once-weekly semaglutide 2.4 mg plus lifestyle intervention for 68 weeks before both the medicine and the trial lifestyle intervention were stopped.
Weight change after stopping
By week 68, average weight loss was 17.3% of initial body weight. Over the next year, the group regained 11.6 percentage points. At week 120, the average participant remained 5.6% below the original starting weight. In practical terms, the group gave back roughly two-thirds of its earlier loss, although some individuals regained less and others more.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsThe extension analysis was exploratory and represented a subset of the original trial, so its results describe that study population and timeline rather than everyone who uses semaglutide. It also cannot establish what would happen after a shorter course, a different dose, or a medically supervised maintenance plan.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Health measurements
Most cardiometabolic improvements measured during treatment moved toward baseline during the year after withdrawal. The published conclusion from the STEP 1 Study Group states: “One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables.”
What the Zepbound withdrawal study found
SURMOUNT-4 design
SURMOUNT-4 was a randomized withdrawal study in adults without diabetes. Everyone first completed a 36-week, open-label tirzepatide lead-in. Average weight reduction during that phase was 20.9%.
Switching to placebo versus continuing treatment
After the lead-in, one group switched from tirzepatide to placebo for 52 weeks. Its mean body weight increased by 14.0% from the week-36 measurement. Another group continued tirzepatide and lost a further 5.5% on average over the same period.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →The result shows what happened under this specific randomized withdrawal design; it does not mean every person who stops Zepbound will gain exactly 14%, nor does it show that continuing treatment produces the same result for every patient. The current U.S. Zepbound prescribing information describes Study 4 as a randomized withdrawal trial in which continued treatment maintained or extended weight reduction relative to switching to placebo. The label is not a personalized stopping or restarting schedule.
How to compare the two studies without being misled
| Feature | STEP 1 extension (semaglutide/Wegovy) | SURMOUNT-4 (tirzepatide/Zepbound) |
|---|---|---|
| Participants | 327 people from STEP 1; obesity or overweight with a comorbidity; no diabetes | Adults without diabetes who completed the randomized-withdrawal protocol |
| Treatment before withdrawal | Semaglutide 2.4 mg and lifestyle intervention for 68 weeks | Open-label tirzepatide for 36 weeks |
| Average loss before withdrawal | 17.3% of initial body weight at week 68 | 20.9% during the 36-week lead-in |
| Withdrawal period | 52 weeks after treatment and lifestyle intervention stopped | 52 weeks after switching to placebo |
| Average result after withdrawal | 11.6 percentage points regained; 5.6% net loss from original baseline at week 120 | 14.0% mean increase in body weight from week 36 |
| Comparator in the same study | No ongoing-treatment comparison in the extension result described here | Participants continuing tirzepatide lost an additional 5.5% on average |
| Other outcomes | Most cardiometabolic improvements moved toward baseline | Continued treatment maintained or extended weight reduction relative to placebo switching |
The table places the figures side by side for orientation, not as a head-to-head contest. The studies differed in lead-in length, participant selection, trial procedures, and the way results were reported. A percentage increase from a post-treatment weight in one trial is not interchangeable with percentage points of lost weight regained in another.
Will you gain all the weight back?
No study cited here says that everyone regains all weight, and neither study predicts an individual outcome. The STEP 1 extension ended with an average net loss of 5.6% from starting weight, which means the average participant had not returned completely to baseline after one year. Individual trajectories can fall above or below that average.
The most defensible expectation from these data is that stopping removes a treatment that was associated with substantial weight loss, and regain is likely enough that it should be part of the decision discussion. Your result may be affected by the reason the medicine was prescribed, the dose and duration used, diabetes status, other medicines, health conditions, eating pattern, activity, and the follow-up plan. Those factors were not tested as a universal prediction formula in these withdrawal studies.
Free tools Windows power users keep installed
One-click scans. No signup required.
Do you need to taper off?
The cited trials do not establish an all-purpose tapering schedule for Wegovy or Zepbound. They also do not provide a universal protocol for a missed dose, a prolonged interruption, or restarting after weight regain. A taper may or may not be appropriate in a particular case, but the decision depends on the product directions and your medical circumstances.
Rank #4
Do not change the dose, stop injections, or restart an old dose on your own. Contact the prescriber for instructions, especially if the medicine is being used alongside treatment for blood-glucose control. A clinician may need to review current glucose readings, other medicines, side effects, pregnancy plans, surgery, dehydration risk, and the reason for stopping before advising what to do next.
What might you feel after the final dose?
The withdrawal evidence establishes average weight and cardiometabolic changes over months; it does not verify a specific symptom timetable after the last injection. It is therefore not possible to give a reliable, universal day-by-day schedule for appetite changes, gastrointestinal symptoms, or other effects from these studies alone.
If you develop severe or persistent symptoms, or if you use the medicine for diabetes and notice unusually high or low glucose readings, seek medical advice promptly. Use the product’s current patient information and your prescriber’s instructions rather than an online timetable.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Why cardiometabolic follow-up matters
Weight is only one outcome. In the STEP 1 extension, most cardiometabolic improvements measured during semaglutide treatment moved toward baseline during the 52-week withdrawal period. That finding means a decision to stop should include monitoring relevant health measures, not just watching the scale.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
- Ask which measurements your clinician wants tracked, such as blood pressure, glucose, cholesterol, or waist circumference.
- Confirm when those measurements should be checked after the final dose.
- Review whether another medicine needs adjustment if weight or glucose changes.
- Report symptoms that could indicate a complication rather than assuming they are an expected part of withdrawal.
A safer decision process before stopping
- Write down the reason for stopping. Cost, side effects, inadequate response, supply problems, pregnancy planning, a procedure, or a change in health status can require different plans.
- Record your current regimen. Bring the product name, dose, injection date, how long you have taken it, recent weight trend, and all other medicines to the appointment.
- Ask what outcome is being prioritized. The plan may focus on weight maintenance, glucose control, reducing side effects, or a temporary interruption.
- Get explicit instructions. Ask whether to take the next dose, hold it, taper, or use a different treatment; when to check in; and what to do if you miss more than one dose.
- Set monitoring points. Agree on the symptoms, home measurements, laboratory tests, and time window that should trigger a call.
- Plan for a change in weight without self-blame. The withdrawal trials show that regain can occur despite effort. A rising trend is a reason to contact the care team, not to double a dose or use someone else’s medicine.
If you have already stopped
Tell the prescribing clinician when your last dose was and whether you stopped abruptly or after a gap. Do not assume that the dose you previously tolerated is automatically the correct restart dose after an interruption. The studies cited here do not define a restart protocol.
Keep a simple record of weight, appetite changes, relevant glucose readings if applicable, side effects, and the names and doses of other medicines. Bring that record to follow-up. If you have diabetes, ask how often to check glucose and which readings require urgent advice. If you are experiencing severe symptoms, contact a medical professional rather than waiting for a routine appointment.
Questions to take to your prescriber
- What is the medical reason to continue, pause, or stop this medicine in my case?
- Is a dose change or taper appropriate for my product and treatment history?
- What should I do if I miss one dose, several doses, or cannot obtain the medicine?
- Which symptoms require same-day advice or emergency care?
- Which glucose, blood-pressure, cholesterol, or other checks should I schedule?
- If weight begins to rise, when should we reassess the plan?
- How do my other medicines, diabetes status, pregnancy plans, or an upcoming procedure affect the decision?
What these studies can—and cannot—tell you
They can tell you
- Regain was observed after withdrawal of both semaglutide and tirzepatide in the cited evidence.
- The average amount regained was substantial over a 52-week follow-up.
- In STEP 1, many cardiometabolic improvements moved toward baseline after semaglutide withdrawal.
- In SURMOUNT-4, continuing tirzepatide produced a different average trajectory from switching to placebo.
They cannot tell you
- Exactly how much weight one particular person will regain.
- Whether a shorter or longer treatment course would produce the same pattern.
- Whether tapering prevents regain or reduces symptoms.
- What dose to restart after an interruption.
- Whether the results apply unchanged to people with diabetes, because the cited withdrawal populations did not have diabetes.
Bottom line for a stopping decision
Stopping Wegovy or Zepbound commonly leads to some weight regain in the available withdrawal trials, but the studies do not prove that every person will regain all lost weight. STEP 1 participants regained about two-thirds of their prior semaglutide-associated loss over one year, while SURMOUNT-4 participants who switched from tirzepatide to placebo gained weight on average and those who continued treatment lost more. Because the trials were separate and their protocols differed, use them as context—not as a personal forecast. Make any stopping, tapering, or restarting decision with the prescribing clinician and include a plan for monitoring weight and relevant health measures.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
